Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StrataMGT vs Estrace in GSM
NCT05672901Recruiting
- Sponsor
- Stratpharma
- Start
- Apr 2023
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Randomised, open-label trial in genitourinary syndrome of menopause (GSM) (2 arms), sponsored by Stratpharma. Primary endpoint: Quality of Life at 3 months. Started Apr 2023; status: recruiting.
02
Conditions
genitourinary syndrome of menopause (GSM)
Beyond the preview
Go deeper on NCT05672901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05672901.